Treatment of Other Bacterial Pneumonia in Adults with Severe Community-Acquired Pneumonia
This protocol covers antibiotic management for adult inpatients who present with severe community-acquired pneumonia and have no identified risk factors for MRSA or Pseudomonas aeruginosa.
Clinical Scenario
Adult inpatient with severe community-acquired pneumonia — defined as meeting one major criterion or three or more minor criteria — without risk factors for MRSA or Pseudomonas aeruginosa.
Treatment Approach
Guidelines recommend a combination antibiotic strategy pairing a β-lactam with either a macrolide or a respiratory fluoroquinolone — the complete agent choices, sequencing, and transition criteria are available in the full protocol.
Treatment Goals
The target endpoint is clinical stability: resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mentation — assessed by day 5 of therapy.
References
DOI: 10.1164/rccm.201908-1581ST
In inpatient adults with severe CAP (see Table 1) without risk factors for MRSA or P. aeruginosa, we recommend (Table 4) (note, specific agents and doses are the same as 9.1):
Validated definition includes either one major criterion or three or more minor criteria.
a b-lactam plus a macrolide (strong recommendation, moderate quality of evidence); or a b-lactam plus a respiratory fluoroquinolone (strong recommendation, low quality of evidence).
We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).
Failure to achieve clinical stability within 5 days is associated with higher mortality and worse clinical outcomes.
View source ↗